Some patients receiving PTU develop a different and a more serious kind of adverse autoimmune response characterized by high titres of antibodies to MPO with clinical manifestations including pauci-immune necrotizing and crescentic glomeruloneprithis, upper respiratory tract disease, and pulmonary hemorrhage with negative or low titres of ANA [9,10]. The gene discussed is BTG3; the disease is respiratory system disorder.